← All trials
NCT02955082
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 25, 2017
- Primary completion
- May 25, 2019
- Completion date
- Apr 25, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 450
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of LondonLead sponsor
- Royal Marsden Hospital NHS TrustOverall official - principal investigator
- Southend University Hospital Foundation NHS TrustCollaborator
- Buckinghamshire Healthcare NHS TrustCollaborator
- European Research CouncilCollaborator
- Colchester Hospital University NHS Foundation TrustCollaborator
- Dartford and Gravesham NHS Foundation TrustCollaborator
- Medway NHS Foundation TrustCollaborator
- Maidstone & Tunbridge Wells NHS TrustCollaborator
- East and North Hertfordshire NHS TrustCollaborator
- Frimley Park Hospital NHS TrustCollaborator
- North Middlesex University Hospital NHS TrustCollaborator
- Heatherwood and Wexham Park Hospitals NHS Foundation TrustCollaborator
- Royal Marsden Hospital NHS TrustCollaborator
- University of LondonCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.